S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
TCRX · TScan Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
TScan Therapeutics Inc (TCRX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.22
-0.01
(-2.62%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.22
$0.22
$0.22
52-WEEK RANGE
$0.22
$0.20
$2.55
What's happening
- TCRX is down 2.62% today, trading at $0.22. — Live quote
- It's trading within 3% of its 52-week low ($0.20). (Finnhub fundamentals)
- Volume today (2,625) is well below its 3-month average of 794,920. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.23 actual vs. $-0.22 estimated (-5.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 4
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TCRX
-77.60%
vs S&P 500
-90.38%
1-YEAR RETURN
TCRX
-91.11%
vs S&P 500
-105.67%
6-MONTH RETURN
TCRX
-79.26%
3-MONTH RETURN
TCRX
-76.18%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.23
Est. $-0.22
MISS -5.0%
2026-04-26 (Q1 2026)
$-0.22
Est. $-0.18
MISS -25.4%
2026-01-26 (Q4 2025)
$-0.18
Est. $-0.25
BEAT +26.8%
2025-10-26 (Q3 2025)
$-0.28
Est. $-0.30
BEAT +7.0%
Valuation Measures & Ratios
Enterprise Value4-$52.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)2.14
Price / Book70.93
EV4 / Revenue-7.34
EV4 / EBITDA—
Profit Margin-1655.35%
Operating Margin-1695.15%
Return on Equity (ROE8)-108.72%
Return on Assets (ROA9)-54.47%
Avg Volume (3M)794,920
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $129.4M | $131.0M | $225.7M | $192.0M | $181.1M |
| P/E | -0.98 | -0.97 | -1.65 | -1.45 | -1.44 |
| Price/Sales | 16.98 | 14.98 | 25.63 | 28.11 | 41.91 |
| Price/Book | 1.87 | 1.35 | 1.57 | 1.09 | 0.86 |
| EV/Revenue | 8.14 | 4.07 | 10.07 | 8.04 | 13.70 |
| ROE | -190.80% | -139.76% | -94.90% | -75.05% | -59.86% |
| ROA | -76.81% | -67.06% | -52.12% | -44.42% | -37.82% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,486,277
Change from Prior Settlement+9.04%
% of Float—
Days to Cover (Short Ratio)3.25
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -65.8% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -1655.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -91.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TCRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $982.0K | $2.5M | $3.1M | $2.2M | $1.0M | $536.0K | $566.0K |
| Operating income | -$30.5M | -$29.1M | -$37.1M | -$38.7M | -$36.2M | -$32.6M | -$34.1M | -$31.4M |
| Net income | -$30.4M | -$28.7M | -$35.7M | -$37.0M | -$34.1M | -$29.9M | -$31.7M | -$30.1M |
| EPS (diluted) | $-0.23 | $-0.22 | $-0.28 | $-0.28 | $-0.26 | $-0.25 | $-0.28 | $-0.32 |
| EPS (basic) | $-0.23 | $-0.22 | $-0.28 | $-0.28 | $-0.26 | $-0.25 | $-0.28 | $-0.32 |
| Operating margin | -$2.9K | -$3.0K | -$1.5K | -$1.3K | -$1.7K | -$3.1K | -$6.4K | -$5.5K |
| Net margin | -$2.9K | -$2.9K | -$1.4K | -$1.2K | -$1.6K | -$2.8K | -$5.9K | -$5.3K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $171.5M | $202.0M | $228.8M | $262.2M | $298.6M | $332.7M | $371.1M | $348.0M |
| Total liabilities | $102.4M | $105.1M | $105.7M | $118.2M | $121.8M | $122.5M | $130.1M | $118.9M |
| Stockholders' equity | $69.0M | $96.9M | $123.1M | $144.0M | $176.7M | $210.2M | $241.0M | $229.1M |
| Total current assets | $104.4M | $132.8M | $157.2M | $188.2M | $221.1M | $254.8M | $292.7M | $274.1M |
| Total current liabilities | $31.0M | $20.0M | $18.7M | $29.2M | $31.3M | $29.8M | $36.0M | $28.7M |
| Cash & equivalents | $100.2M | $128.1M | $152.4M | $169.5M | $169.4M | $154.1M | $178.7M | $133.1M |
| Marketable securities (current) | — | — | — | $14.9M | $48.7M | $97.6M | $111.4M | $138.0M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $7.7M | $8.1M | $8.7M | $9.3M | $9.5M | $8.4M | $7.2M | $7.5M |
| Accounts payable | $3.1M | $2.3M | $1.2M | $6.4M | $4.5M | $5.0M | $4.3M | $3.6M |
| Deferred revenue (current) | $586.0K | $1.6M | $2.6M | $5.2M | $7.7M | $10.3M | $11.7M | $9.9M |
| Short-term debt | $11.7M | — | — | — | — | — | — | — |
| Long-term debt | $21.1M | $32.7M | $32.5M | $32.4M | $32.3M | $32.2M | $32.1M | $30.6M |
| Other non-current liabilities | — | — | — | $278.0K | $113.0K | $124.0K | $135.0K | $146.0K |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$563.9M | -$533.5M | -$504.9M | -$481.9M | -$446.2M | -$409.2M | -$375.1M | -$339.3M |
| Accumulated other comprehensive income (loss) | — | — | — | $2.0K | -$4.0K | -$4.0K | $51.0K | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.5M | -$24.3M | -$32.0M | -$32.5M | -$33.3M | -$37.6M | -$27.4M | -$27.9M |
| Investing cash flow | -$465.0K | -$70.0K | $14.8M | $32.6M | $48.4M | $13.5M | $27.3M | -$82.4M |
| Financing cash flow | $99.0K | — | $73.0K | $0 | $116.0K | -$525.0K | $45.7M | $1.2M |
| Free cash flow | -$28.0M | -$24.3M | -$32.2M | -$33.9M | -$34.5M | -$39.1M | -$28.3M | -$29.3M |
| Capital expenditures | $493.0K | $70.0K | $171.0K | $1.4M | $1.3M | $1.5M | $888.0K | $1.4M |
| Share-based compensation | $2.4M | $2.5M | $2.0M | $3.0M | $3.3M | $3.4M | $2.7M | $2.5M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $843.0K | $1.0M | -$5.1M | $1.9M | -$435.0K | $558.0K | $983.0K | $1.0M |
| Purchases of investments | — | — | $0 | -$1.0K | $26.5M | $60.9M | $47.3M | $137.0M |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M |
| Operating income | -$135.8M | -$134.8M | -$93.5M | -$66.6M | -$48.6M |
| Net income | -$129.8M | -$127.5M | -$89.2M | -$66.2M | -$48.6M |
| EPS (diluted) | $-1.00 | $-1.14 | $-1.36 | $-2.75 | $-4.17 |
| EPS (basic) | $-1.00 | $-1.14 | $-1.36 | $-2.75 | $-4.17 |
| Operating margin | -$1.3K | -$4.8K | -$444 | -$492 | -$480 |
| Net margin | -$1.3K | -$4.5K | -$424 | -$489 | -$479 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $228.8M | $371.1M | $272.1M | $199.1M | $188.1M |
| Total liabilities | $105.7M | $130.1M | $121.3M | $99.7M | $27.3M |
| Stockholders' equity | $123.1M | $241.0M | $150.9M | $99.4M | $160.8M |
| Total current assets | $157.2M | $292.7M | $194.2M | $124.1M | $165.7M |
| Total current liabilities | $18.7M | $36.0M | $29.8M | $17.3M | $21.3M |
| Cash & equivalents | $152.4M | $178.7M | $133.4M | $120.0M | $161.4M |
| Marketable securities (current) | — | $111.4M | $58.7M | — | — |
| Property, plant & equipment | $8.7M | $7.2M | $7.7M | $10.1M | $11.8M |
| Accounts payable | $1.2M | $4.3M | $2.4M | $2.9M | $1.8M |
| Deferred revenue (current) | $2.6M | $11.7M | $10.1M | $3.9M | $11.4M |
| Short-term debt | — | — | $3.3M | — | — |
| Long-term debt | $32.5M | $32.1M | $26.7M | $29.3M | — |
| Other non-current liabilities | — | $135.0K | — | $49.0K | $97.0K |
| Retained earnings | -$504.9M | -$375.1M | -$247.6M | -$158.4M | -$92.2M |
| Accumulated other comprehensive income (loss) | — | $51.0K | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$135.3M | -$110.8M | -$61.4M | -$66.5M | -$48.7M |
| Investing cash flow | $109.4M | -$52.6M | -$60.8M | -$4.2M | -$9.9M |
| Financing cash flow | -$336.0K | $208.8M | $135.4M | $29.4M | $189.7M |
| Free cash flow | -$139.7M | -$114.6M | -$64.5M | -$70.7M | -$58.6M |
| Capital expenditures | $4.4M | $3.8M | $3.1M | $4.2M | $9.9M |
| Share-based compensation | $11.7M | $9.5M | $5.2M | $4.6M | $2.5M |
| Change in accounts payable | -$3.0M | $2.0M | -$52.0K | $528.0K | $10.0K |
| Purchases of investments | $87.5M | $241.4M | $77.6M | — | — |
| Debt issued | — | — | — | $29.4M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TCRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-19 to 2026-10-01
Recent transactions
- Most recent: MacBeath Gavin (Chief Executive Officer) — Grant / award of 1,000,000 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| MacBeath Gavin | Chief Executive Officer | Grant / award | 2026-10-01 | 1,000,000 |
| ZDRAVESKI ZORAN | See Remarks | Grant / award | 2026-10-01 | 300,000 |
| Lynx1 Capital Management LP | 10% owner | Open market purchase | 2025-12-23 | 6,232 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | MacBeath Gavin | Chief Executive Officer | Grant / award | 1,000,000 | $0.00 |
| 2026-10-01 | ZDRAVESKI ZORAN | See Remarks | Grant / award | 300,000 | $0.00 |
| 2025-12-23 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 6,232 | $0.90 |
| 2025-12-22 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 75,500 | $0.90 |
| 2025-12-19 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 80,069 | $0.90 |
| 2025-05-20 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 1,200,000 | $1.20 |
| 2025-05-19 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 1,388,794 | $1.20 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-18 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-22 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-22 | 8-K | 2026-05-20 | View on SEC.gov → |
Recent news
Headlines about TCRX (TScan Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Form PRE 14A Tscan Therapeutics Inc For: 16 October
Investing.com India · 2026-10-17 -
TCRX PRE 14A & SEC Filings
Yahoo Finance · 2026-10-16 -
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow
Seeking Alpha · 2026-09-04 -
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
Seeking Alpha · 2026-09-02 -
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
Yahoo Finance · 2026-09-02 -
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
Yahoo Finance · 2026-09-02 -
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
Yahoo Finance · 2026-08-12 -
TScan Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.05M misses by $0.83M
Seeking Alpha · 2026-08-12
No headlines in this category right now — try “All”.